GLP1: How Indian pharma giants positioning for a fat obesity/Diabetes windfall

Indian pharma giants are positioning for a multi-billion dollar windfall!

GLP-1 drugs (think Ozempic) are revolutionizing diabetes/obesity treatment but supply can't keep up with demand. With key patents expiring in March 2026, Indian CDMOs like OneSource & Gland Pharma are scaling up to fill the gap